Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2022-09-27 00:00:00 ET · period of report 2022-09-26 · accession 0000899243-22-032164 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-27 | 2022-09-26 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $5.51 | -1,264 | 253.5K | -0.5% | -$6,965 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2022-09-26 | S | D | 1,264 | $5.51 | 253,520 | D | — | — | (F2) The Common Shares were sold in one transaction at a price of $7.60 CAD Dollars. This represents the price in United States Dollars using the conversion rate on September 26, 2022. |